You are here

News

Genome Canada welcomes five new Board members

Wednesday, October 30, 2013

Genome Canada is delighted to highlight the recent appointment of five new members to its Board of Directors. They include:

Fiona Brinkman, Professor, Molecular Biology and Biochemistry at Simon Fraser University

Jay Ingram, Broadcaster and Science Writer

Kim McConnell, Founder and former CEO, AdFarm

Moura Quayle, Professor, Strategic Design, Sauder School of Business, University of British Columbia

Donald Ziraldo, Co-founder, Inniskillin Wines

The Structural Genomics Consortium Announces that Janssen has joined its Public-Private Drug Discovery Partnership

Friday, October 25, 2013

The Structural Genomics Consortium (SGC) announced today that Janssen Pharmaceuticals NV has joined its group to partner in the investigation of epigenetics-based drug research, a new and burgeoning field in the development of future medicines.

Genome Canada congratulates Abdallah Daar on appointment to new UN Scientific Advisory Board

Monday, October 21, 2013

Dr. Abdallah Daar, Professor of Public Health at the University of Toronto and a Genome Canada Board member since 2012, has been appointed to a new Scientific Advisory Board of the United Nations. Dr. Daar is one of twenty-six eminent scientists appointed to the Board, representing natural, social and human sciences and engineering.

Dawn of a new era for children: Introducing Canada’s first integrated clinical genomic centre in pediatrics

Monday, October 21, 2013

Dr. Fabrice Brunet, Chief Executive Officer at Sainte-Justine UHC, and Marc LePage, President and CEO of Génome Québec, are extremely proud to announce the launch of Canada’s first integrated clinical genomic centre in pediatrics, an initiative currently at the forefront of global efforts in this area. "We are honoured to have the opportunity to make this partnership a reality in the presence of the Québec Premier, Pauline Marois, and Dr.

Research Catalyst Network: Rare Diseases

Thursday, October 17, 2013

The goal of the “Research Catalyst Network: Expediting collaboration between basic and clinician scientists in functional studies of novel rare disease genes” is to establish a national consortium that will enable clinical geneticists who are identifying rare disease gene mutations to collaborate with model organism researchers with expertise in the cognate gene’s function.

Pages